Analysts forecast that Celsion Co. (NASDAQ:CLSN) will report sales of $130,000.00 for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Celsion’s earnings. The company is expected to issue its next quarterly earnings report on Tuesday, March 26th.
According to Zacks, analysts expect that Celsion will report full-year sales of $500,000.00 for the current fiscal year. For the next fiscal year, analysts anticipate that the firm will post sales of $500,000.00. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for Celsion.
Celsion (NASDAQ:CLSN) last released its quarterly earnings data on Thursday, November 15th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.04). Celsion had a negative net margin of 4,282.33% and a negative return on equity of 104.30%. The company had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $0.13 million.
A number of brokerages recently commented on CLSN. Brookline Cap M reaffirmed a “buy” rating on shares of Celsion in a research note on Tuesday, November 20th. Zacks Investment Research lowered Celsion from a “buy” rating to a “hold” rating in a research note on Tuesday, November 13th. Oppenheimer set a $9.00 price target on Celsion and gave the stock a “buy” rating in a research note on Thursday, November 15th. Finally, ValuEngine raised Celsion from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st.
An institutional investor recently raised its position in Celsion stock. Vanguard Group Inc. increased its holdings in Celsion Co. (NASDAQ:CLSN) by 40.9% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 740,132 shares of the biotechnology company’s stock after acquiring an additional 214,829 shares during the quarter. Vanguard Group Inc. owned about 3.95% of Celsion worth $2,050,000 as of its most recent filing with the Securities & Exchange Commission. 5.09% of the stock is currently owned by hedge funds and other institutional investors.
Shares of CLSN stock opened at $1.95 on Friday. Celsion has a 52 week low of $1.68 and a 52 week high of $3.48. The firm has a market capitalization of $35.59 million, a P/E ratio of -0.82 and a beta of 1.46. The company has a quick ratio of 3.84, a current ratio of 3.84 and a debt-to-equity ratio of 0.62.
Celsion Company Profile
Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials to treat recurrent chest wall breast cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.